dsRNA binding characterization of full length recombinant wild type and mutants Zaire ebolavirus VP35.

Authors:
Address: Department of Life and Environmental Sciences, University of Cagliari, Cittadella di Monserrato SS554, 09042 Monserrato, Cagliari, Italy.
Journal:

Publication:

abstract

The Ebola viruses (EBOVs) VP35 protein is a multifunctional major virulence factor involved in EBOVs replication and evasion of the host immune system. EBOV VP35 is an essential component of the viral RNA polymerase, it is a key participant of the nucleocapsid assembly and it inhibits the innate immune response by antagonizing RIG-I like receptors through its dsRNA binding function and, hence, by suppressing the host type I interferon (IFN) production. Insights into the VP35 dsRNA recognition have been recently revealed by structural and functional analysis performed on its C-terminus protein. We report the biochemical characterization of the Zaire ebolavirus (ZEBOV) full-length recombinant VP35 (rVP35)-dsRNA binding function. We established a novel in vitro magnetic dsRNA binding pull down assay, determined the rVP35 optimal dsRNA binding parameters, measured the rVP35 equilibrium dissociation constant for heterologous in vitro transcribed dsRNA of different length and short synthetic dsRNA of 8bp, and validated the assay for compound screening by assessing the inhibitory ability of auryntricarboxylic acid (IC(50) value of 50μg/mL). Furthermore, we compared the dsRNA binding properties of full length wt rVP35 with those of R305A, K309A and R312A rVP35 mutants, which were previously reported to be defective in dsRNA binding-mediated IFN inhibition, showing that the latter have measurably increased K(d) values for dsRNA binding and modified migration patterns in mobility shift assays with respect to wt rVP35. Overall, these results provide the first characterization of the full-length wt and mutants VP35-dsRNA binding functions.

Related Articles
Structure of the Ebola VP35 interferon inhibitory domain.
Proc Natl Acad Sci U S A. 2009
Structure of the Ebola VP35 interferon inhibitory domain.
Leung DW, Ginder ND, Fulton DB, Nix J, Basler CF, Honzatko RB, Amarasinghe GK. Proc Natl Acad Sci U S A. 2009 Jan 13; 106(2):411-6. Epub 2009 Jan 2.
Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling.
J Virol. 2006
Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling.
Cárdenas WB, Loo YM, Gale M Jr, Hartman AL, Kimberlin CR, Martínez-Sobrido L, Saphire EO, Basler CF. J Virol. 2006 Jun; 80(11):5168-78.
Mutations abrogating VP35 interaction with double-stranded RNA render Ebola virus avirulent in guinea pigs.
J Virol. 2010
Mutations abrogating VP35 interaction with double-stranded RNA render Ebola virus avirulent in guinea pigs.
Prins KC, Delpeut S, Leung DW, Reynard O, Volchkova VA, Reid SP, Ramanan P, Cárdenas WB, Amarasinghe GK, Volchkov VE, et al. J Virol. 2010 Mar; 84(6):3004-15. Epub 2010 Jan 13.
Review Evasion of interferon responses by Ebola and Marburg viruses.
J Interferon Cytokine Res. 2009
Review Evasion of interferon responses by Ebola and Marburg viruses.
Basler CF, Amarasinghe GK. J Interferon Cytokine Res. 2009 Sep; 29(9):511-20.
Review The kinase complex responsible for IRF-3-mediated IFN-beta production in myeloid dendritic cells (mDC).
J Biochem. 2006
Review The kinase complex responsible for IRF-3-mediated IFN-beta production in myeloid dendritic cells (mDC).
Sasai M, Matsumoto M, Seya T. J Biochem. 2006 Feb; 139(2):171-5.

To top • Home

TraveldoctorOnline 2001 • Disclaimer • webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.